Galmed Pharmaceuticals Ltd. (GLMD) CSO details option holdings

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. Chief Scientific Officer Liat Nissimov Brueck filed an initial statement of beneficial ownership, reporting direct holdings of employee stock options. These options allow her to purchase Ordinary Shares at an exercise price of 68.4000 per share, with individual grants covering 222, 181 and 153 underlying shares. The options have staggered exercise and expiration dates ranging from 2016-09-06 to 2030-11-10, showing a series of long-term equity awards rather than new market transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nissimov Brueck Liat

(Last) (First) (Middle)

C/O MEITAR LAW OFFICES

16 ABBA HILLEL SILVER RD.

(Street)

RAMAT GAN 5250608

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Galmed Pharmaceuticals Ltd. [ GLMD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares	11/10/2020	11/10/2030	Ordinary Shares	222	$68.4	D
Options to Purchase Ordinary Shares	12/17/2019	12/17/2029	Ordinary Shares	222	$68.4	D
Options to Purchase Ordinary Shares	07/10/2018	07/10/2028	Ordinary Shares	222	$68.4	D
Options to Purchase Ordinary Shares	01/31/2017	01/31/2027	Ordinary Shares	181	$68.4	D
Options to Purchase Ordinary Shares	09/06/2016	09/06/2026	Ordinary Shares	153	$68.4	D

Explanation of Responses:

	/s/ Liat Hayardeny Nissimov	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Galmed (GLMD) Chief Scientific Officer report on this Form 3?

The Chief Scientific Officer reports existing holdings of stock options to purchase Ordinary Shares. These are compensation-related awards, not recent market trades, and establish her baseline derivative ownership position in Galmed Pharmaceuticals Ltd. as of the filing date.

How many Galmed options are reported by the Chief Scientific Officer?

The filing lists several option grants, including positions over 222, 181 and 153 underlying Ordinary Shares. Each grant is shown separately, reflecting multiple awards rather than a single large option position, and together they outline her current derivative stake in the company.

What is the exercise price of the Galmed options held by the CSO?

All reported option grants carry an exercise price of 68.4000 per Ordinary Share. This means the Chief Scientific Officer can buy Galmed shares at that fixed price, regardless of the market price, if she chooses to exercise within each grant’s term.

When do the Galmed CSO’s option grants expire?

The option grants have staggered expiration dates between 2026-09-06 and 2030-11-10. Earlier grants, such as one dated 2016-09-06, expire sooner, while later grants extend the potential exercise window, creating a ladder of long-dated equity incentives.

Are there recent insider purchases or sales in this Galmed Form 3?

The Form 3 does not show recent insider purchases or sales of Galmed shares. It records existing holdings of options to purchase Ordinary Shares, providing an initial snapshot of the Chief Scientific Officer’s derivative ownership rather than documenting new trading activity.

What type of security does the Galmed CSO hold according to the Form 3?

The filing shows the Chief Scientific Officer holds “Options to Purchase Ordinary Shares.” Each option grant is tied to a specific number of underlying Ordinary Shares and a 68.4000 exercise price, giving her the right, but not the obligation, to acquire equity in the future.